X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (383135) 383135
Newspaper Article (31301) 31301
Newsletter (4201) 4201
Book Chapter (2532) 2532
Web Resource (1627) 1627
Dissertation (797) 797
Magazine Article (269) 269
Publication (217) 217
Book / eBook (146) 146
Trade Publication Article (129) 129
Conference Proceeding (118) 118
Government Document (104) 104
Reference (30) 30
Book Review (23) 23
Streaming Video (15) 15
Paper (3) 3
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (294275) 294275
life sciences & biomedicine (260782) 260782
humans (197756) 197756
animals (171539) 171539
kinases (135874) 135874
proteins (82381) 82381
mice (79232) 79232
phosphorylation (75538) 75538
oncology (75389) 75389
male (72491) 72491
signal transduction (69499) 69499
cell biology (65920) 65920
female (61893) 61893
biochemistry & molecular biology (59721) 59721
apoptosis (57211) 57211
gene expression (49895) 49895
rats (47288) 47288
research (46117) 46117
cell line, tumor (45458) 45458
cancer (45076) 45076
cells, cultured (40411) 40411
research article (37387) 37387
mutation (34216) 34216
cell cycle (32383) 32383
science & technology - other topics (32350) 32350
multidisciplinary sciences (31718) 31718
signal transduction - drug effects (31375) 31375
cell line (31286) 31286
medicine (31125) 31125
protein kinases (29544) 29544
analysis (29347) 29347
enzyme inhibitors - pharmacology (28902) 28902
tumors (27644) 27644
pharmacology & pharmacy (27132) 27132
rodents (26830) 26830
science (25312) 25312
cell proliferation (25070) 25070
genetic aspects (25024) 25024
physiological aspects (24985) 24985
middle aged (24502) 24502
health aspects (24146) 24146
neurosciences (23656) 23656
apoptosis - drug effects (23530) 23530
protein kinase inhibitors - pharmacology (23473) 23473
biology (23260) 23260
neurosciences & neurology (21535) 21535
physiology (21485) 21485
studies (20867) 20867
cell growth (20352) 20352
adult (20295) 20295
metastasis (19499) 19499
inflammation (19475) 19475
blotting, western (19289) 19289
aged (19243) 19243
immunology (19215) 19215
cancer therapies (19151) 19151
care and treatment (18827) 18827
cell proliferation - drug effects (18784) 18784
protein-serine-threonine kinases - metabolism (18190) 18190
dose-response relationship, drug (18187) 18187
medicine, research & experimental (17858) 17858
research & experimental medicine (17838) 17838
enzymes (17575) 17575
biochemistry (17527) 17527
enzyme activation (17024) 17024
rats, sprague-dawley (16980) 16980
breast cancer (16834) 16834
antineoplastic agents - pharmacology (16808) 16808
phosphorylation - drug effects (16492) 16492
mice, inbred c57bl (16359) 16359
abridged index medicus (16310) 16310
genes (15899) 15899
cytokines (15808) 15808
protein binding (15577) 15577
protein kinase c - metabolism (15497) 15497
signal transduction - physiology (15081) 15081
time factors (15067) 15067
immunohistochemistry (14947) 14947
medical research (14867) 14867
transfection (14823) 14823
hematology (14585) 14585
chemotherapy (14499) 14499
mitogen-activated protein kinases - metabolism (14359) 14359
signaling (14191) 14191
proto-oncogene proteins c-akt - metabolism (13940) 13940
protein kinase inhibitors - therapeutic use (13927) 13927
development and progression (13894) 13894
tyrosine (13873) 13873
stem cells (13754) 13754
deoxyribonucleic acid--dna (13656) 13656
tumor cells, cultured (13496) 13496
disease models, animal (13258) 13258
metabolism (13065) 13065
lung cancer (12973) 12973
transcription factors (12745) 12745
molecular sequence data (12708) 12708
life sciences (12632) 12632
chemistry (12524) 12524
binding sites (12491) 12491
phosphatidylinositol 3-kinases - metabolism (12146) 12146
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (72) 72
Gerstein Science - Stacks (34) 34
Collection Dvlpm't (Acquisitions) - Vendor file (11) 11
Chemistry (A D Allen) - Stacks (3) 3
UofT at Mississauga - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (420779) 420779
Chinese (2614) 2614
Japanese (2541) 2541
French (853) 853
German (714) 714
Russian (551) 551
Portuguese (264) 264
Spanish (199) 199
Korean (195) 195
Polish (129) 129
Czech (82) 82
Norwegian (79) 79
Hungarian (74) 74
Italian (69) 69
Dutch (50) 50
Turkish (29) 29
Ukrainian (29) 29
Danish (23) 23
Croatian (17) 17
Swedish (12) 12
Slovak (11) 11
Finnish (10) 10
Hebrew (6) 6
Bulgarian (4) 4
Latin (4) 4
Serbian (4) 4
Romanian (3) 3
Slovenian (3) 3
Persian (2) 2
Afrikaans (1) 1
Arabic (1) 1
Catalan (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 07/2017, Volume 35, Issue 19, pp. 2193 - 2202
.... We hypothesize the programmed death-ligand 1 (PD-L1) inhibitor, durvalumab, olaparib, or cediranib combinations are tolerable and active in recurrent women's cancers... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
Chemical biology & drug design, ISSN 1747-0277, 01/2011, Volume 77, Issue 1, pp. 1 - 11
The BCR‐ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia... 
kinase | ponatinib | AP24534 | drug discovery | X‐ray crystallography | structure‐based drug design | X-ray crystallography | Structure-based drug design | Drug discovery | Ponatinib | Kinase | Pharmacology & Pharmacy | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Piperazines - chemistry | Structure-Activity Relationship | Pyridazines - pharmacology | Pyridazines - chemical synthesis | Pyrimidines - chemistry | Protein Kinase Inhibitors - chemistry | Protein Binding - drug effects | Imidazoles - chemical synthesis | Imidazoles - therapeutic use | Pyridazines - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Imidazoles - pharmacology | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Animals | Mutation - drug effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Benzamides | Fluoroimmunoassay | Fusion Proteins, bcr-abl - metabolism | Drug Resistance, Neoplasm - drug effects | Drug resistance | Analysis | Leukemia | Index Medicus | STRUCTURE-ACTIVITY RELATIONSHIPS | MUTANTS | BASIC BIOLOGICAL SCIENCES | ENZYME INHIBITORS | TYROSINE | GENE MUTATIONS | PHOSPHOTRANSFERASES | MYELOID LEUKEMIA | MUTATIONS | ANTINEOPLASTIC DRUGS | 60 APPLIED LIFE SCIENCES | RESIDUES
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2015, Volume 372, Issue 18, pp. 1689 - 1699
AZD9291, an irreversible inhibitor of epidermal growth factor receptor, was associated with tumor responses in the majority of patients with advanced non... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aniline Compounds - administration & dosage | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Aniline Compounds - pharmacokinetics | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Patient outcomes | Tyrosine | Appetite | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Diarrhea | Nausea | Drug resistance | Kinases | Patients | Epidermal growth factor | Pharmacokinetics | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
International journal of cancer, ISSN 0020-7136, 08/2015, Volume 137, Issue 3, pp. 686 - 697
Around 70% of breast cancers express the estrogen receptor α (ERα) and depend on estrogen for growth, survival and disease progression. The presence of hormone... 
Her2 inhibition | proteasome inhibition | estrogen receptor alpha inhibition | Life Sciences & Biomedicine | Oncology | Science & Technology | Receptors, Estrogen - metabolism | Prognosis | TOR Serine-Threonine Kinases - metabolism | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Agents - therapeutic use | Phosphatidylinositol 3-Kinases - metabolism | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Tumor Suppressor Protein p53 - genetics | Breast Neoplasms - metabolism | Neoplasm Metastasis | Receptor, Epidermal Growth Factor - metabolism | Estrogen Receptor alpha - metabolism | Female | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Gene Expression Regulation, Neoplastic - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Disease Models, Animal | Bortezomib | Receptors, Estrogen - genetics | Proteasome Inhibitors - pharmacology | Signal Transduction | Tumor Suppressor Protein p53 - metabolism | Breast Neoplasms - drug therapy | Proteasome Inhibitors - therapeutic use | Xenograft Model Antitumor Assays | Animals | Breast Neoplasms - pathology | Cell Line, Tumor | Breast Neoplasms - mortality | Pyrazines - pharmacology | Boronic Acids - pharmacology | Mitogen-Activated Protein Kinases - metabolism | Estrogen | Phenols | Development and progression | Breast cancer | Hormones | Tumor proteins | Medical prognosis | Mortality | Endocrine therapy | Mammography | Kinases | Cancer therapies | Tumors | Index Medicus
Journal Article
PloS one, ISSN 1932-6203, 02/2017, Volume 12, Issue 2, pp. e0171221 - e0171221
Journal Article
International journal of cancer, ISSN 0020-7136, 01/2018, Volume 142, Issue 1, pp. 202 - 213
...) inhibitor ibrutinib, have demonstrated notable therapeutic effects in relapsed/refractory patients, which indicate that pharmacological inhibition of BCR pathway holds promise in MCL treatment... 
mTOR inhibitor | targeted therapy | BTK inhibitor | drug combination | Mantle cell lymphoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Everolimus - pharmacol